As of 2023, the imports of Streptomycins to China were valued slightly lower than 443.83 thousand US dollars, marking a baseline for subsequent forecasts. From 2024 to 2028, the import values show a steady upward trend, with predictions reaching up to 530.35 thousand US dollars by 2028. The year-on-year percentage increase indicates a consistent growth rate in demand. On average, the compound annual growth rate (CAGR) over this forecasted period remains positive, showing a healthy growth trajectory in the imports of Streptomycins into China.
Future trends to watch for include the impact of China's domestic pharmaceutical production capabilities, potential tariff changes, and global supply chain adjustments, which may affect the import volumes and values. Furthermore, monitoring health policy shifts and antibiotic demand based on changing healthcare practices will be crucial in predicting future import needs.
